---
title: "Bruce C. Cozadd，爵士製藥的董事長兼首席執行官，報告了出售普通股的情況"
description: "爵士製藥 plc 的董事長兼首席執行官 Bruce C. Cozadd 報告了公司普通股的處置。完整的文件可通過提供的鏈接獲取。此消息由公共技術公司生成，僅供信息參考，不應被視為財務、投資或法律建議"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/238803917.md"
published_at: "2025-05-05T23:01:14.000Z"
---

# Bruce C. Cozadd，爵士製藥的董事長兼首席執行官，報告了出售普通股的情況

> 爵士製藥 plc 的董事長兼首席執行官 Bruce C. Cozadd 報告了公司普通股的處置。完整的文件可通過提供的鏈接獲取。此消息由公共技術公司生成，僅供信息參考，不應被視為財務、投資或法律建議

爵士製藥公司（Jazz Pharmaceuticals plc）的董事長兼首席執行官布魯斯·C·科扎德（Bruce C. Cozadd）報告了該公司普通股的處置。完整的文件可以通過以下鏈接訪問。免責聲明：本新聞簡報由公共技術公司（Public Technologies，PUBT）使用生成性人工智能創建。儘管 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。爵士製藥公司通過美國證券交易委員會（U.S. Securities and Exchange Commission）運營的電子數據收集、分析和檢索系統（EDGAR）於 2025 年 5 月 5 日發佈了用於生成本新聞簡報的原始內容（參考 ID：0001765581-25-000039），並對此信息的內容承擔全部責任。© 版權 2025 - 公共技術公司（PUBT）原始文件：這裏

### Related Stocks

- [JAZZ.US - 爵士制藥](https://longbridge.com/zh-HK/quote/JAZZ.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results | Jazz Pharmaceuticals (JAZZ) has gained attention following positive Phase 3 results for its HER2-targeted drug Ziihera i | [Link](https://longbridge.com/zh-HK/news/271933572.md) |
| What Analysts Are Saying About Jazz Pharmaceuticals Stock | Analysts have provided mixed ratings for Jazz Pharmaceuticals (NASDAQ:JAZZ) over the past three months, with 11 analysts | [Link](https://longbridge.com/zh-HK/news/272265895.md) |
| Jazz Pharmaceuticals Showcases Rare Disease Breakthroughs and Growth Strategy in New Presentation | Jazz Pharmaceuticals plc presented at the 44th Annual J.P. Morgan Healthcare Conference, showcasing its achievements and | [Link](https://longbridge.com/zh-HK/news/272449426.md) |
| Jazz Pharmaceuticals Completes Acquisition of Chimerix | Jazz Pharmaceuticals has acquired Chimerix, integrating it into its corporate strategy. The acquisition includes the Pha | [Link](https://longbridge.com/zh-HK/news/272282470.md) |
| Jazz Pharmaceuticals Announce Positive Efficacy From Ziihera Phase 3 Trial | Jazz Pharmaceuticals PLC :ZIIHERA® (ZANIDATAMAB-HRII) COMBINATIONS ACHIEVE UNPRECEDENTED RESULTS IN FIRST-LINE HER2+ LOC | [Link](https://longbridge.com/zh-HK/news/271691426.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。
